Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLOWR phase 3 trial of lisaftoclax added to acalabrutinib in previously treated CLL/SLL without complete response after at least 12 months of acalabrutinib
MOH_2024-05-15_013411Phase 3Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Lisaftoclax + acalabrutinib with Acalabrutinib alone (2 arms). Primary endpoint: Progression-free survival. Started Mar 2024; status: recruiting.
02
Drugs
lisaftoclaxacalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2024-05-15_013411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-15_013411.